title: Flavopiridol: where do we stand in chronic lymphocytic leukemia?
authors.affiliation: Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: T S
authors.initials: TS
authors.lastname: Lin
authors.forename: P
authors.initials: P
authors.lastname: Porcu
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D005419:Flavonoids; D010880:Piperidines; D016159:Tumor Suppressor Protein p53; C077990:alvocidib; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases